Eiger BioPharmaceuticals Inc EIGR

NAS: EIGR | ISIN: US28249U1051 27/09/2024

8,500 USD (0,00%)

(0,00%) 27/09/2024

Grafiek Eiger BioPharmaceuticals Inc

Grafiek Eiger BioPharmaceuticals Inc

1 dag1d 0,00%
1 week1w 0,00%
1 maand1m 0,00%
3 maanden3m 0,00%
6 maanden6m 0,00%
1 jaar1j 254,17%
5 jaar5j 17,73%

Eiger BioPharmaceuticals Inc in het nieuws

Toon enkel gratis nieuws

18 januari 2024 · Eiger and Partner, AnGes, Receive Approval for Zokinvy® (lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan · Persbericht

4 januari 2024 · Eiger BioPharmaceuticals, Inc. Announces 1-for-30 Reverse Stock Split · Persbericht

9 november 2023 · Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update · Persbericht

12 september 2023 · Eiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis Delta · Persbericht

5 september 2023 · Eiger BioPharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference · Persbericht

14 augustus 2023 · Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update · Persbericht

29 juni 2023 · Eiger BioPharmaceuticals to Focus on Metabolic Diseases with Avexitide; David Apelian Takes Helm as CEO · Persbericht

28 juni 2023 · Eiger BioPharmaceuticals to Host Business Update Call Tomorrow · Persbericht

11 mei 2023 · Eiger BioPharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update · Persbericht

3 mei 2023 · Eiger BioPharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) · Persbericht

Profiel Eiger BioPharmaceuticals Inc

Gezondheidstechnologie

Productie van biologische producten

Website: www.eigerbio.com

Hoofdzetel: Palo Alto, California Verenigde Staten

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe